Research analysts at JMP Securities lifted their price objective on shares of InterMune (NASDAQ:ITMN) from $48.00 to $55.00 in a report released on Thursday. JMP Securities’ price objective would suggest a potential upside of 30.83% from the company’s current price. InterMune Inc. (NASDAQ:ITMN) weekly performance is 7.39%. On last trading day company shares ended up $43.89. Analysts mean target price for the company is $40.79. InterMune Inc. (NASDAQ:ITMN) distance from 50-day simple moving average (SMA50) is 26.52%.
Vital Therapies, Inc. (NASDAQ:VTL), a biotherapeutic company developing a cell-based therapy targeting the treatment of acute liver failure, on 28 may announced financial results for the quarter ended March 31, 2014, and provided an update on recent operations. Vital Therapies reported a net loss for the quarter ended March 31, 2014 of $10.7 million and, after the accretion of redemption value and deemed dividends on our preferred stock, a net loss attributable to our common stockholders of $13.8 million. Vital Therapies Inc. (NASDAQ:VTL) shares advanced 12.04% in last trading session and ended the day on $32.11.
TG Therapeutics, Inc. (NASDAQ:TGTX), an innovative, clinical-stage biopharmaceutical company on 30 may announced clinical results from its ongoing Phase I single agent study of TG-1101 (ublituximab), the Company’s novel glycoengineered anti-CD20 monoclonal antibody and from its ongoing first-in-human Phase I single agent study of TGR-1202, the Company’s oral, once-daily, PI3K delta inhibitor. TG Therapeutics, Inc. (NASDAQ:TGTX) shares moved up 20.82% in last trading session and was closed at $8.82, while trading in range of $7.19 – $8.89. TG Therapeutics, Inc. (NASDAQ:TGTX) year to date (YTD) performance is 126.15%.
Alder BioPharmaceuticals, Inc., (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing therapeutic antibodies for the treatment of migraine, autoimmune and inflammatory diseases, announced that members of Alder’s senior management team will present at Wells Fargo Securities 2014 Healthcare Conference on Tuesday, June 17, 2014. Alder Biopharmaceuticals Inc. (NASDAQ:ALDR) ended the last trading day at $18.70. Company weekly volatility is calculated as 10.43% and price to cash ratio as 24.10.Alder Biopharmaceuticals Inc. (NASDAQ:ALDR) showed a positive weekly performance of 20.72%.
BioSpecifics Technologies Corp. (NASDAQ:BSTC) Director Henry Morgan sold 17,940 shares of the company’s stock on the open market in a transaction that occurred on Wednesday, June 4th. The stock was sold at an average price of $27.00, for a total value of $484,380.00. Following the transaction, the director now directly owns 17,193 shares in the company, valued at approximately $464,211. BioSpecifics Technologies Corp. (NASDAQ:BSTC) net profit margin is 32.60% and weekly performance is 2.81%. On last trading day company shares ended up $27.78. Analysts mean target price for the company is $38.33. BioSpecifics Technologies Corp. (NASDAQ:BSTC) distance from 50-day simple moving average (SMA50) is 8.33%.
Leave a Reply